WA-UNAVETS
20.9.2021 14:05:05 CEST | Business Wire | Press release
UNAVETS (“UNAVETS”), a European platform for veterinary centers with over 43 practices across Spain and Portugal, announced today their partnership with Petabyte Technology (“Petabyte”), a leading veterinary software company, to join the newly established Petabyte Consortium, which is focused on cleaning and standardizing data to improve veterinary practices across the world.
Petabyte revolutionizes patient management for veterinary hospitals through its suite of software solutions, including Rhapsody, a cloud-based Practice Information Management System (PIMS); Petabyte Analytics, an enterprise-level analytics platform; and Boop, a mobile application simplifying the pet care experience for pet parents. With innovative features such as standardized data, comprehensive wellness plans, virtual check-in, on-the-go communications, and a built-in payment system, Petabyte enables doctors to deliver exceptional care to pets and their families.
“Petabyte was founded with a mission to simplify veterinary operations to help doctors and staff care for pets and their families,” said Michael Hyman, Co-Founder and Chief Executive Officer of Petabyte. “UNAVETS’ mission of supporting vets so they can focus on delivering the best healthcare is a goal we share, making this collaboration a natural choice. Furthermore, partnering with UNAVETS is another step towards setting the industry standard on a global level through next-generation software.”
UNAVETS’ corporate group will start by leveraging Petabyte’s analytics platform as they continue to expand across EMEA, switching to localized versions of Petabyte’s products as they roll out. As the Petabyte Consortium continues to expand, Petabyte and UNAVETS invite other forward-thinking veterinary partners and groups to collaborate on using Petabyte’s software to transform the future of pet care on a global stage through Petabyte’s suite of software solutions. UNAVETS is the third group to join Petabyte’s Consortium with more updates expected to be released as the Consortium continues to welcome new partners.
“UNAVETS’ key focus is elevating the level of healthcare for all pets and their families. This partnership was formed because we strongly believe that Petabyte’s next generation software will expand our ability to support that mission on multiple fronts,” comments Junko Sheehan, Founder and Chief Executive Officer of UNAVETS. “The ‘customer journey’ of today’s pet parents requires a digitally forward-thinking approach with mobile check-in, check-out, digital records, seamless online booking, etc., and we believe that Petabyte’s next generation of software is capable of providing this and much more. As the pandemic has increased the demand for veterinary healthcare worldwide, we hope that providing best-in-class software solutions to clinics will be important to alleviate excess demands on our vets, so they can focus on what they love doing – providing the best care for our pets.”
Founded in 2019, Petabyte’s mission is to give veterinary healthcare practitioners greater understanding and control over their business using cloud-based technology. Petabyte is a unique enterprise practice management solution that allows veterinary practices to run more efficient operations and deliver better patient veterinary care. Petabyte considers a practice’s needs by offering a product that emphasizes a simple design and intuitive usability. It also offers robust customer support through teams equipped to assist veterinary practices, both large and small. The company brings together unique talent with decades of experience in the veterinary industry and in building cutting-edge technology to deliver the best practice management solution on the market. For more information, please visit petabyte.technology .
UNAVETS has grown to over 43 practices and a team of over 385 employees across Spain and Portugal since January 2020. UNAVETS’ continued mission is to elevate the standard of healthcare for pets via continued professional development and operations. We offer practices that join our group real support and collaboration in HR/professional development, operations, IT, marketing/digital, finance and accounting, and facilities/equipment management via our corporate team of over 30 individuals. In December 2019, UNAVETS was financed with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). Oaktree is a leader among global investors specializing in alternative investments, managing $140 billion in assets as of September 30, 2020. Oaktree’s core European strategy manages more than €4.5 billion in assets under management. For more information, please visit unavets.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
